Jane Street’s Neumora Therapeutics NMRA Stock Holding History

Jane Street’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,300	Closed	-$23.8K	–	12528
2025 Q4	$23.8K	Sell	13,300 -13,200	-50%	-$28.9K	﹤0.01%	10693
2025 Q3	$48.2K	Buy	26,500 +6,000	+29%	+$9.7K	﹤0.01%	10364
2025 Q2	$15K	Buy	20,500 +10,500	+105%	+$7.96K	﹤0.01%	9383
2025 Q1	$10K	Sell	10,000 -176,300	-95%	-$302K	﹤0.01%	9206
2024 Q4	$1.97M	Buy	186,300 +135,400	+266%	+$1.62M	﹤0.01%	4122
2024 Q3	$672K	Buy	+50,900	New	+$594K	﹤0.01%	6657

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Jane Street's NMRA Position: Q1 2026 in Review

Jane Street reduced its Neumora Therapeutics (NMRA) stake by 34% in Q1 2026, selling an estimated $988K and leaving 747,665 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5699.

Jane Street first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.02M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

Jane Street held 747,665 shares of Neumora Therapeutics worth $1.46M as of Q1 2026.
Jane Street sold 381,307 Neumora Therapeutics shares in Q1 2026, an estimated $988K.
Neumora Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5699 holding.
Jane Street first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
Jane Street's Neumora Therapeutics position peaked at $2.02M in Q4 2025.
114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.